Debra A. Bell

TL;DR: It is reported that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1,BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes.

TL;DR: Wide variation in the expression of the DNA cytosine deaminase APOBEC3B is reported, with elevated expression in the majority of ovarian cancer cell lines and high-grade primary ovarian cancers, identifying a potential role for APOBec3B in serous ovarian cancer genomic instability.

TL;DR: It is shown that, in the context of undifferentiated endometrial sarcomas, recognition of cytomorphologic features on routine hematoxylin and eosin–stained sections may be used to select tumors with specific molecular genetic changes—that is, translocations involving YWHAE.

TL;DR: A unifying model of ovarian epithelial tumorigenesis that takes into account various hypotheses is proposed and novel approaches to overcome the major problem of chemoresistance in ovarian cancer are reviewed.

TL;DR: If a myxoid background is appreciated in a spindle cell lesion of the female genital tract, especially if inflammatory cells are present, anaplastic lymphoma kinase-1 staining along with fluorescence in situ hybridization studies, for ALK gene rearrangements, may aid in distinguishing inflammatory myofibroblastic tumors from their malignant mimics.